Emerging research suggest this peptide, a dual stimulator targeting both incretin and GIP , could provide a notable development for weight treatment. Initial human trials have shown impressive decreases in body tissue, possibly exceeding current obesity medications . However , additional assessment is needed to thoroughly determine its long-term ef